免疫系统
埃利斯波特
菌斑减少中和试验
免疫学
抗体
接种疫苗
病毒学
中和抗体
改良安卡拉痘苗
医学
免疫
病毒
抗原
生物
牛痘
T细胞
重组DNA
基因
生物化学
作者
Elke Jordan,Steven J. Lawrence,Thomas Meyer,Darja Schmidt,Stephanie A. Schultz,Jutta Mueller,Daria Stroukova,Brigitte Koenen,Robert Gruenert,Guenter Silbernagl,Sanja Vidojkovic,Liddy M Chen,Heinz Weidenthaler,Nathaly Samy,Paul Chaplin
标识
DOI:10.1093/infdis/jiaa460
摘要
Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in young children and the elderly. Protective immunity is not generated after repeated infections, but vaccination may hopefully prove effective.This phase 2 clinical study investigated a multivalent RSV vaccine (MVA-BN-RSV) designed to induce broad antibody and cellular immune responses by encoding RSV surface proteins F, G (for both A and B subtypes), and internal antigens (M2, N). This study evaluated the immune response in adults aged ≥55 years to identify the optimal MVA-BN-RSV dose and vaccination schedule.A single dose increased the levels of neutralizing (plaque reduction neutralization test to RSV A and B) and total (IgG and IgA ELISA) antibodies (1.6 to 3.4-fold increase from baseline) and induced a broad Th1-biased cellular immune response (interferon-γ ELISPOT) to all 5 vaccine inserts (5.4 to 9.7-fold increases). Antibody responses remained above baseline for 6 months. A 12-month booster dose elicited a booster effect in antibody and T-cell responses (up to 2.8-fold from preboost levels). No drug-related serious adverse events were reported.MVA-BN-RSV induces a broad immune response that persists at least 6 months and can be boosted at 12 months, without significant safety findings.NCT02873286.
科研通智能强力驱动
Strongly Powered by AbleSci AI